CD63 and prostate carcinoma: In urine, the level of CD9 positive and CD63 positive EV have been shown to be higher in men with prostate cancer [73], as well as in plasma (Figure 4), supporting the clinical utility of CD9 positive EV measurement in patients biofluids for men with prostate cancer.